AI Biomarker for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if specific biomarkers in blood or tumor tissue can identify the best pre-surgery treatment for pancreatic ductal adenocarcinoma. Participants will receive one of two standard chemotherapy treatments: FOLFIRINOX or Gemcitabine with Nab-paclitaxel. The study targets individuals with pancreatic cancer that is either resectable (can be surgically removed) or borderline resectable (almost removable but might need treatment first). Those diagnosed with one of these conditions who have not received prior chemotherapy may be suitable for this trial.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to an important step in treatment development.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores using an AI-derived biomarker to help select the best neoadjuvant (pre-surgery) treatment for pancreatic ductal adenocarcinoma patients. What sets this approach apart is its potential to tailor treatment plans based on individual patient characteristics, possibly leading to more effective outcomes. Typically, standard care involves chemotherapy, but this method aims to enhance precision in treatment selection, potentially improving the likelihood of successful surgeries and better long-term results. By using AI to guide treatment choices, this trial could pave the way for more personalized cancer care strategies.
Who Is on the Research Team?
Christos Fountilas, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants undergo standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Blood sample
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Pathological response of Patients with resectable disease (per NCCN criteria) treated with standard care chemotherapy
Pathological response of Patients with borderline resectable disease (per NCCD Criteria) treated with standard care chemotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Roswell Park Cancer Institute
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.